Radioligand therapy (RLT) has emerged as an effective therapeutic modality for the management of disseminated metastatic cancers. Current radiotheranostic strategies predominantly rely on biological vectors targeting membrane-bound, cancer-specific antigens. In this study, we identify the embryonic guidance cue netrin-1, an extracellular matrix-associated protein, as an unexpected and promising target for targeted alpha therapy (TAT). Netrin-1 is upregulated in multiple human malignancies, including metastatic breast and lung cancers, promoting tumor cell survival, proliferation and invasion. Accordingly, the monoclonal antibody NP137 was developed and has undergone initial safety and efficacy evaluation in several Phase I and II trials in patients with advanced solid tumors.
HERVIEU Maeva;
VINCK Robin;
MINGOT Maxime;
KRYZA D.;
CHAIB Sarah;
COUDERC Marie;
SIDI BOUMEDINE Jacqueline;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
MEHLEN Patrick;
WALTER Thomas;
GIBERT Benjamin;
2026-05-04
ELSEVIER INC.
JRC145580
1876-7982 (online),
https://www.sciencedirect.com/science/article/pii/S1939865426000494,
https://publications.jrc.ec.europa.eu/repository/handle/JRC145580,
10.1016/j.jmir.2026.102235 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
